Evidence map›Paper›PMID 40181083›Full record

ArticleScientific reports2025

A stratified precision screening strategy for enhancing hepatitis B- and C-associated liver cancer detection: a prospective study.

Hua He, Yanhua Wu, Zhifang Jia, Yangyu Zhang, Yuchen Pan, Yuzheng Zhang, Kaisheng Su, Yingnan Cui, Yuanlin Sun, Dongming Li and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Hua He *Department of Clinical Epidemiology, the First Hospital of Jilin University, No. 1, Xinmin Street, Changchun, 130021, Jilin Province, China.
Yanhua Wu *Department of Clinical Epidemiology, the First Hospital of Jilin University, No. 1, Xinmin Street, Changchun, 130021, Jilin Province, China.
Zhifang JiaDepartment of Clinical Epidemiology, the First Hospital of Jilin University, No. 1, Xinmin Street, Changchun, 130021, Jilin Province, China.
Yangyu ZhangDepartment of Clinical Epidemiology, the First Hospital of Jilin University, No. 1, Xinmin Street, Changchun, 130021, Jilin Province, China.
Yuchen PanDepartment of Clinical Epidemiology, the First Hospital of Jilin University, No. 1, Xinmin Street, Changchun, 130021, Jilin Province, China.
Yuzheng ZhangDepartment of Clinical Epidemiology, the First Hospital of Jilin University, No. 1, Xinmin Street, Changchun, 130021, Jilin Province, China.
Kaisheng SuDepartment of Clinical Epidemiology, the First Hospital of Jilin University, No. 1, Xinmin Street, Changchun, 130021, Jilin Province, China.
Yingnan CuiDepartment of Clinical Epidemiology, the First Hospital of Jilin University, No. 1, Xinmin Street, Changchun, 130021, Jilin Province, China.
Yuanlin SunDepartment of Clinical Epidemiology, the First Hospital of Jilin University, No. 1, Xinmin Street, Changchun, 130021, Jilin Province, China.
Dongming LiDepartment of Clinical Epidemiology, the First Hospital of Jilin University, No. 1, Xinmin Street, Changchun, 130021, Jilin Province, China.
Haiyong LvDepartment of Clinical Epidemiology, the First Hospital of Jilin University, No. 1, Xinmin Street, Changchun, 130021, Jilin Province, China.
Jiaxin YiDepartment of Clinical Epidemiology, the First Hospital of Jilin University, No. 1, Xinmin Street, Changchun, 130021, Jilin Province, China.
Yuehui WangDepartment of Geriatrics, the First Hospital of Jilin University, Changchun, 130021, Jilin Province, China.
Changgui KouDepartment of Epidemiology and Biostatistics, School of Public Health, Jilin University, Changchun, 130021, Jilin Province, China.
Xiaofeng SunDepartment of Cadre's Wards Ultrasound Diagnostics, Ultrasound Diagnostic Center, the First Hospital of Jilin University, Changchun, 130021, Jilin Province, China.
Jing JiangDepartment of Clinical Epidemiology, the First Hospital of Jilin University, No. 1, Xinmin Street, Changchun, 130021, Jilin Province, China. jiangjing19702000@jlu.edu.cn.

Funding

National Natural Science Foundation of China 82204116Scientific and Technological Development Program of Jilin Province 20200403098SF
6 · The paper itself

Abstract

This study explores new screening strategies to enhance liver cancer screening effectiveness. In a prospective study, 2605 participants underwent baseline, 6-months self-reported, and 1-year follow-up screenings using abdominal ultrasonography, AFP, AFP-L3%, and DCP. The results demonstrated the GALADUS protocol exhibited superior performance with higher AUC (0.935 vs. 0.836; DeLong P < 0.001), sensitivity (91.0% vs. 70.8%; P < 0.001), detection (3.1% vs. 2.4%; P < 0.001), and early diagnosis rates (64.2% vs. 58.7%) compared to the AFP/US protocol. Notably, among individuals with an aMAP score ≥ 60, GALADUS had significantly outperformed AFP/US in AUC (0.923 vs. 0.826; DeLong P < 0.001), sensitivity (94.2% vs. 69.6%; P < 0.001), detection (9.7% vs. 7.2%; P < 0.001), and early diagnosis rates (63.1% vs. 54.2%). However, for those with an aMAP score < 60, GALADUS offered no significant advantages. Introducing the "aMAP triage" protocol, combining GALADUS for aMAP ≥ 60 and AFP/US for aMAP < 60, further enhanced AUC to 0.925 (DeLong P < 0.001), improved sensitivity by 19.1% (89.9% vs. 70.8%; P < 0.001), and increased detection (3.1% vs. 2.4%; P < 0.001) and early diagnosis rates (65.0% vs. 58.7%), being cost-effective compared to GALADUS. In conclusion, this study highlights the potential of a stratified precision screening strategy in identifying high-risk individuals, applying tailored early detection protocols to improve liver cancer screening efficacy.

Indexed as

Early Detection of CancerHepatitis BHepatitis CLiver NeoplasmsAdultAgedalpha-FetoproteinsFemaleHumansMaleMass ScreeningMiddle AgedProspective StudiesUltrasonographyalpha-FetoproteinsaMAP scoreGALADUS scoreLiver cancerProspective screeningStratified screening

Identifiers

PMID40181083
PMCPMC11968812

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.